Abstract
Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Current Drug Therapy
Title: Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis
Volume: 5 Issue: 4
Author(s): Christine Chang, David Bezov and Marco Pappagallo
Affiliation:
Keywords: Chronic pain, ketamine, major depressive disorder, neuropathic pain, nmda receptor antagonist, opioid tolerance, opioid resistance, analgesic, hyperalgesia, dysthymia, antidepressant, neurotransmitters, glutamate receptor, synaptic plasticity, coincidence detector, cholinergic receptors, kappa opioid receptors, psychomimetic, serotonin, anesthetic effect, cerebral vasodilation, hallucinations, nightmares, morphine, benzodiazepine, tachyarrhythmias, schizophrenia, allodynia, lidocaine, postherpetic neuralgia, xerostomia, Limb Pain, Fibromyalgia, Pluronic lecithin organogel, Stump/Phantom, Whiplash Pain, Placebo-controlled, Montgomery, –, Asberg Depression Rating Scale, lamotrigine, epidural, Opioidergic, Glutamatergic Dysfunction, naloxone
Abstract: Chronic Pain syndromes and Major Depressive Disorder account for two of the most costly and prevalent illnesses worldwide and are frequently comorbid and treatment resistant. In this review, we examine the current role of ketamine, a potent NMDA (N-methl-D-aspartic acid) receptor blocker, in treating chronic pain and major depression. The role of the NMDA receptor and glutamatergic system are increasingly being studied in mood disorders, and are known components in pain processing, opioid induced analgesic tolerance, and hyperalgesia. We propose a hypothetic therapeutic role of ketamine involving the opioidergic pathway in these patients with treatment resistant chronic pain and major depressive disorder.
Export Options
About this article
Cite this article as:
Chang Christine, Bezov David and Pappagallo Marco, Ketamine for Chronic Pain and Treatment Resistant Depression: A Mechanistic Hypothesis, Current Drug Therapy 2010; 5 (4) . https://dx.doi.org/10.2174/157488510792927447
DOI https://dx.doi.org/10.2174/157488510792927447 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents on Technologies of Human Tissue and Organ Regeneration from Pluripotent Human Embryonic Stem Cells
Recent Patents on Regenerative Medicine Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4
CNS & Neurological Disorders - Drug Targets Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry The Role of Amino Acids in the Modulation of Cardiac Metabolism During Ischemia and Heart Failure
Current Pharmaceutical Design Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry Directed Differentiation of Pluripotent Cells Towards Therapeutic Stem Cells
Recent Patents on Regenerative Medicine Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Nonnucleoside Inhibitors of Adenosine Kinase
Current Pharmaceutical Design Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Cytochrome P450 in Neurological Disease
Current Drug Metabolism The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Anesthesia and Postoperative Cognitive Dysfunction (POCD)
Central Nervous System Agents in Medicinal Chemistry High Mobility Group Box 1 Protein as a Potential Drug Target for Infection- and Injury-Elicited Inflammation
Inflammation & Allergy - Drug Targets (Discontinued)